PHARMAPRINT INC
10-Q, EX-27.1, 2000-11-20
PHARMACEUTICAL PREPARATIONS
Previous: PHARMAPRINT INC, 10-Q, EX-10.19, 2000-11-20
Next: BENIHANA INC, 10-Q, 2000-11-20



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-2001
<PERIOD-END>                               SEP-30-2000
<CASH>                                         427,636
<SECURITIES>                                         0
<RECEIVABLES>                                  224,240
<ALLOWANCES>                                   224,240
<INVENTORY>                                    500,000
<CURRENT-ASSETS>                             1,098,052
<PP&E>                                         644,563
<DEPRECIATION>                                 498,255
<TOTAL-ASSETS>                               1,744,360
<CURRENT-LIABILITIES>                       14,638,888
<BONDS>                                        196,401
                                0
                                          7
<COMMON>                                        20,906
<OTHER-SE>                                (13,011,642)
<TOTAL-LIABILITY-AND-EQUITY>                 1,744,360
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                        1,187,822
<TOTAL-COSTS>                                1,187,822
<OTHER-EXPENSES>                             1,170,904
<LOSS-PROVISION>                               222,298
<INTEREST-EXPENSE>                              81,222
<INCOME-PRETAX>                            (1,935,542)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,935,542)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,935,542)
<EPS-BASIC>                                   (0.11)
<EPS-DILUTED>                                   (0.11)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission